&w=3840&q=100)
Emcure Pharma rises over 2% as USFDA issues Form 483 with Zero observations
At 11:25 AM, Emcure Pharma share price continued to trade higher, up 1.39 per cent at ₹1,273.60. In comparison, BSE Sensex was trading 0.39 per cent lower at 83,206.68 levels.
Why did Emcure Pharma share price rise today?
Emcure Pharma share price rose in trade after the company announced that United States Food and Drug Administration (USFDA) issued Form 483 with zero observations, post pre-approval inspection (PAI), for its Sanand, Ahmedabad unit.
The inspection was held between June 30, 2025 and July 8, 2025.
In an exchange filing, Emcure Pharma said, 'This is to inform you that the United States Food and Drug Administration (USFDA) had conducted Pre-Approval Inspection (PAI) of Company's manufacturing facility (Oncology) located at GIDC, Taluka - Sanand, Ahmedabad, Gujarat, from June 30, 2025 to July 08, 2025. The inspection concluded without issuance of Form 483 (zero observations).'
Emcure Pharma IPO listing
Emcure Pharmaceuticals listed on the exchanges on July 10 last year i.e. 2024. The company made a solid debut with its shares listing at ₹1,325, a 31 per cent premium over its issue price of ₹1,008, on the National Stock Exchange (NSE) and BSE.
About Emcure Pharma
Emcure Pharma, headquartered in Pune, is among the leading global pharmaceutical companies recognised for its strong commitment to innovation, quality, and patient-centricity.
Established in 1981, Emcure Pharmaceuticals has developed a diverse portfolio of pharmaceutical products across various therapeutic areas, aiming to improve patient health and well-being.
As a research and development-driven organisation, the company specialises in manufacturing differentiated medicines designed to address the evolving needs of patients worldwide.
Moreover, the company has established a major presence in over 70 countries, including key markets like Europe and Canada.
With a focus on advancing healthcare through cutting-edge research and a broad product range, Emcure Pharmaceuticals continues to enhance its global footprint and contribute to the improvement of healthcare outcomes globally.
The market capitalisation of Emcure Pharma is ₹24,135.78 crore, according to BSE. The company falls under the BSE 500 category.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
25 minutes ago
- Mint
Top three stocks to buy today—recommended by Ankush Bajaj for 1 August
The Nifty50 fell by 86.70 points, or 0.35%, on Thursday, closing at 24,768.35. The BSE Sensex dropped 296.28 points, or 0.36%, settling at 81,185.58. The Bank Nifty also continued to slide, losing 188.75 points, or 0.34%, to close at 55,961.95, breaching key intraday support levels and reflecting continued pressure in financials. Top three stocks recommended by Ankush Bajaj for 1 August Market Wrap On Thursday, July 31, 2025,the Nifty 50 fell by 86.70 points or 0.35%, closing at 24,768.35, while the BSE Sensex dropped 296.28 points or 0.36%, settling at 81,185.58. The Bank Nifty also continued to slide, losing 188.75 points or 0.34% to close at 55,961.95, breaching key intraday support levels and reflecting continued pressure in financials. Sectorally, the market faced sharp losses, especially in cyclicals. The Oil & Gas sector declined 1.48%, the Pharma index fell 1.31%, and the Metal index dropped 1.22%, pulling the broader indices down. However, a few defensives offered limited relief — the FMCG sector surged 1.44%, while the Consumption index edged up by 0.33%, reflecting selective investor rotation. Among top performers, Hindustan Unilever stood out with a strong gain of 3.44%, followed by Jio Finance at 2.79%, and Eternal, which rose 1.43%, supported by continued buying in high-quality and lower-beta names. On the downside, heavyweights dragged the market further. Adani Enterprises plunged 4.03% amid valuation concerns, while Tata Steel dropped 2.12%, and Sun Pharma fell 1.56%, extending the pressure on broader sentiment. Nifty Technical Analysis Daily & Hourly On July 31, 2025, the Nifty closed at 24,768.35, down 86.70 points or 0.35%, marking a weak session after recent attempts to stabilize. While the index managed to trade above the key support zone of 24,700 during the session, it failed to sustain higher levels and remained under pressure, once again halting near the major resistance at 25,000. This continued rejection reinforces the fact that 25,000 remains a strong psychological and technical barrier, and unless it is decisively crossed, the market is likely to stay range-bound. From a technical standpoint, the Nifty is currently trading below all its key short-term moving averages. The 20-day SMA stands at 25,119, while the 40-day EMA is placed at 24,994 — both levels the index needs to reclaim to revive near-term bullishness. On the intraday chart, Nifty is also hovering below the 20-hour SMA at 24,803 and the 40-hour EMA at 24,855, which indicates a mildly bearish structure in the short term. Momentum indicators offer little comfort. The daily RSI remains weak at 41, while the hourly RSI has edged up slightly to 44 but still remains below neutral territory. The MACD on both daily (−86) and hourly (−12) timeframes continues to linger in negative territory, suggesting that bearish momentum, although not accelerating, is yet to fade meaningfully. In the derivatives segment, the data continues to show a cautious undertone. Total Call open interest stands at 6.24 crore versus 5.63 crore on the Put side, resulting in a negative difference of 60.73 lakh contracts — a bearish sign. The change in open interest during the day also remains slightly negative, with Call OI rising by 2.85 crore and Put OI increasing by 2.76 crore, resulting in a net bearish bias of 9.28 lakh contracts. The Put-Call Ratio, however, has improved to 0.90, indicating some reduction in bearish sentiment but still not enough to signal a reversal. The highest Call OI is placed at the 26,000 strike, reinforcing a distant upside cap, while 25,000 continues to act as the immediate ceiling. On the Put side, maximum OI remains at the 24,000 strike, establishing it as a strong base. Meanwhile, India VIX ticked up 3% to 11.54, indicating a slight rise in volatility and caution. In summary, the Nifty remains stuck in a consolidation phase with limited directional clarity. The failure to break and hold above 25,000 keeps the short-term trend neutral to bearish. While the index is holding above 24,700 support for now, traders should watch this level closely. A sustained move above 25,000–25,120 is essential for a meaningful bullish breakout, whereas a breakdown below 24,700 could drag the index towards 24,500–24,400. Until then, range-bound and tactical trading strategies such as "buy-on-dips" near support and "sell-on-rise" near resistance are likely to dominate. Ankush Bajaj is a Sebi-registered research analyst. His registration number is INH000010441. Investments in securities are subject to market risks. Read all the related documents carefully before investing. Registration granted by Sebi and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Disclaimer: The views and recommendations given in this article are those of individual analysts. These do not represent the views of Mint. We advise investors to check with certified experts before making any investment decisions.
&w=3840&q=100)
Business Standard
3 hours ago
- Business Standard
Brokerages size up US's trade punch: Tariff impact seen as limited
Brokerages are hopeful that the final tariff may land lower - 15-20% - as both nations continue to negotiate a solution Puneet Wadhwa New Delhi Listen to This Article Donald Trump's 25% tariff on Indian goods rattled markets, with the BSE Sensex dropping nearly 800 points intraday before staging a smart recovery. Brokerages are hopeful that the final tariff may land lower — 15–20% — as both nations continue to negotiate a solution. Here's how brokerages are reading the situation: Goldman Sachs · A 25% tariff, if enforced, would moderately dent earnings due to India's low export exposure · Only 2% of MSCI India's total revenues come from goods exports · Every 5-percentage point increase in US tariffs could shave
Business Standard
11 hours ago
- Business Standard
INR recovers from record low levels but broader outlook remains cautious
The Indian rupee recovered 22 paise from its all-time low to 87.58 (provisional) against the US dollar on Thursday, amid lower crude prices and slight pullback in dollar. US President Donald Trump's announcement of 25 per cent tariffs on Indian imports and a penalty for buying Russian Crude has severely dragged the rupee to lifetime lows in the previous session. Yesterday, rupee plunged 89 paise, logging its steepest single-day fall in over three years and recovered some lost ground today but the broader outlook remains cautious. Indian shares fluctuated before ending lower on Thursday as U.S. President Donald Trump imposed a 25 percent tariff on India starting August 1, along with an additional unspecified penalty for buying oil and defense equipment from Russia. The benchmark BSE Sensex fluctuated before ending the session down 296.28 points, or 0.36 percent, at 81,185.58 while the broader NSE Nifty index closed at 24,768.35, down 86.70 points, or 0.35 percent, from its previous close. At the interbank foreign exchange, the domestic unit opened at 87.66 against the greenback, touched an intra-day low of 87.74 and a high of 87.51 against the American currency. On the NSE, USDINR futures rose 0.25% to 87.78.
